D. W. Müller
Heidelberg University
7 Papers
D. W. Müller is an academic researcher from Heidelberg University. The author has contributed to research in topics: Internal medicine & Clinical endpoint. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Excess Mass Estimates and Tests for Multimodality
D. W. Müller,Günther Sawitzki +1 more
TL;DR: In this article, a method for analyzing the modality of a distribution is proposed based on the excess mass functional, which measures excessive empirical mass in comparison with multiples of uniform distribution.
287
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Georg Martin Haag,Christoph Springfeld,Barbara Grün,Leonidas Apostolidis,Stefanie Zschäbitz,Mareike Dietrich,Anne Berger,Tim Frederik Weber,Inka Zoernig,Marina Schaaf,Lisa Waberer,D. W. Müller,Salah-Eddin Al-Batran,Niels Halama,Dirk Jaeger +14 more
TL;DR: PICCASSO as mentioned in this paper is a phase I trial exploring safety and efficacy of pembrolizumab and maraviroc in refractory mismatch repair proficient (MMRp) colorectal cancer.
65
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial
Farastuk Bozorgmehr,Petros Christopoulos,In Jae Chung,Jelena Cvetkovic,Manuel Feisst,Johannes Krisam,Marc A. Schneider,Claus Peter Heussel,Michael Kreuter,D. W. Müller,Mike Thomas,Stefan Rieken +11 more
TL;DR: The TREASURE trial as discussed by the authors investigated whether treatment efficacy can be improved by adding thoracic radiotherapy to atezolizumab maintenance therapy in ED SCLC patients with any response after chemo-immunotherapy.
1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
A. Atmaca,D. W. Müller,T. Habibzada,M. Schaaf,J. Klagges,R. Eickhoff,E. Jäger,S. Al-Batran,T.O. Goetze +8 more
TL;DR: This study evaluates the feasibility and efficacy of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas, showing promising signals of efficacy and safety in 21 enrolled patients.
3
955P IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
A. Vogel,A. Saborowski,G.M. Siegler,J. Siebler,U. Lindig,M. Schultheiss,T. Mueller,H. Simon,C. Jöckel,D. W. Müller,S. Al-Batran,E. De Toni +11 more
TL;DR: This single-arm phase II trial (NCT03841201) evaluated nivolumab + lenvatinib in 50 advanced HCC patients, achieving 32% ORR, 9.0 mo median PFS, and 25.36 mo median OS, with manageable toxicity, warranting further investigation.